Abstract
The marine natural product, marinopyrrole A (1), was previously shown to have significant antibiotic activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Although compound (1) exhibits a significant reduction in MRSA activity in the presence of human serum, we have identified key modifications that partially restore activity. We previously reported our discovery of a chloro-derivative of marinopyrrole A (1a) featuring a 2-4 fold improved minimum inhibitory concentration (MIC) against MRSA, significantly less susceptibility to serum inhibition and rapid and concentration-dependent killing of MRSA. Here, we report a novel fluoro-derivative of marinopyrrole A (1e) showing an improved profile of potency, less susceptibility to serum inhibition, as well as rapid and concentration-dependent killing of MRSA.
Original language | English (US) |
---|---|
Pages (from-to) | 2458-2470 |
Number of pages | 13 |
Journal | Marine Drugs |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - May 2014 |
Keywords
- Antibiotics
- MRSA
- Non-symmetrical marinopyrroles
- SAR
ASJC Scopus subject areas
- Pharmaceutical Science
- Drug Discovery
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)